CMC Biologics and IDT Biologika GmbH have entered a strategic collaboration aimed at providing more complete and efficient services for the manufacture of antibody drug conjugates (ADCs).   CMC Biologics will perform process development and manufacture of the bulk monoclonal antibody and IDT Biologika will perform services from conjugation of the cytotoxic drug to the antibody substance through to aseptic fill, finish and packaging of the final ADC drug product. This joint manufacturing servic...